Medicare Part D open enrollment and what recent changes mean for beneficiaries

It’s that time of year again: Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their...
Read More
Many seniors are paying more for Part D medicines than their insurer

For seniors who rely on Medicare Part D, the out-of-pocket costs for medicines can sometimes be a barrier. Insurers and pharmacy benefit managers (PBMs) continue to shift more and more costs to...
Read More
A key fact the White House is reluctant to admit

Today, President Biden delivered remarks that touch on recent drug pricing reforms included in the Inflation Reduction Act. While the law is deeply flawed and government price-setting is the wrong...
Read More
The Senate’s latest price setting proposal will undermine: Patient access to medicines

Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...
Read More
Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...
Read More
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

Medicare Part D provides prescription drug coverage for our nation’s seniors and Americans with disabilities. These beneficiaries can opt to enroll in Part D and pick from a variety of plans offered....
Read More
It’s a new year, but sadly Congress is still pursuing flawed price setting policies

As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...
Read More
Post-approval research save lives. Why is Congress trying disincentivize it?

While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...
Read More
A price control by any other name would still put patients at risk and threaten innovation

Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the...
Read More
New data show insurers and PBMs increase barriers to care

New data show insurers and middlemen known as pharmacy benefit managers (PBMs) are making it harder for patients to get the medicines they need.
Read More